Intech Investment Management LLC Boosts Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Intech Investment Management LLC grew its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 32.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 33,935 shares of the biopharmaceutical company’s stock after buying an additional 8,303 shares during the period. Intech Investment Management LLC owned 0.05% of Celldex Therapeutics worth $858,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its stake in shares of Celldex Therapeutics by 1.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 538,856 shares of the biopharmaceutical company’s stock valued at $18,316,000 after acquiring an additional 8,413 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in Celldex Therapeutics by 210.6% in the 3rd quarter. Fisher Asset Management LLC now owns 374,352 shares of the biopharmaceutical company’s stock valued at $12,724,000 after purchasing an additional 253,808 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Celldex Therapeutics by 293.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company’s stock worth $958,000 after purchasing an additional 21,013 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Celldex Therapeutics by 6.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,595 shares of the biopharmaceutical company’s stock worth $3,487,000 after buying an additional 6,269 shares in the last quarter. Finally, Bellevue Group AG raised its position in shares of Celldex Therapeutics by 3.4% in the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock valued at $104,404,000 after buying an additional 100,000 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts recently issued reports on CLDX shares. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Friday, February 28th. UBS Group initiated coverage on Celldex Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $44.00 price objective on the stock. The Goldman Sachs Group dropped their target price on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Morgan Stanley started coverage on Celldex Therapeutics in a research note on Thursday. They issued an “overweight” rating and a $46.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.33.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $19.64 on Monday. The business’s 50-day simple moving average is $22.22 and its 200-day simple moving average is $27.02. The firm has a market capitalization of $1.30 billion, a P/E ratio of -7.64 and a beta of 1.76. Celldex Therapeutics, Inc. has a 1-year low of $18.61 and a 1-year high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. On average, equities research analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.